secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0000078003-24-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance
----------------------------------------------------------------------------

- Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.
- Q4 2023 revenues $14.2B, down 42% operationally; reported diluted LPS $(0.60), adjusted EPS $0.10.
- Ex-COVID products grew 7% operationally in FY2023 (8% in Q4); Seagen acquisition closed Dec 2023 for $44B.
- FY2024 revenue guidance $58.5-61.5B, adj EPS $2.05-2.25; expects $4B cost savings by end 2024.
- No share repurchases planned in 2024; $9.2B dividends paid in FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/pfe-20240130.htm
  HTML page:      https://secwatch.observer/filing/0000078003-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer